PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

@article{Frattini2007PTENLO,
  title={PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients},
  author={Milo Frattini and Piercarlo Saletti and Elena Romagnani and Vittoria Martin and Francesca Molinari and Morena Ghisletta and A Camponovo and Lesly Etienne and Franco Cavalli and Luca Mazzucchelli},
  journal={British Journal of Cancer},
  year={2007},
  volume={97},
  pages={1139 - 1145}
}
To evaluate whether the epidermal growth factor receptor (EGFR), K-Ras and PTEN, all members of the EGFR signalling pathway, may affect the clinical response in cetuximab-treated metastatic colorectal cancer (mCRC) patients. Twenty-seven cetuximab-treated mCRC patients were evaluated for drug response and investigated for EGFR protein expression and gene status, K-Ras mutational status and PTEN protein expression. Ten patients achieved a partial response (PR) to cetuximab-based therapy. All 27… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 288 CITATIONS, ESTIMATED 58% COVERAGE

Oncogenic mutations as predictive factors in colorectal cancer

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND

FILTER CITATIONS BY YEAR

2007
2019

CITATION STATISTICS

  • 9 Highly Influenced Citations

  • Averaged 8 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Different genetic features associated with colon and rectal carcinogenesis.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004
VIEW 4 EXCERPTS

Clinical relevance of KRas mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy

F Di Fiore, F Bianchard, +13 authors T Frebourg
  • Br J Cancer 96:
  • 2007
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

MABEL-A large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
VIEW 1 EXCERPT